title: Short-term effect of zoledronic acid upon fracture resistance of the mandibular condyle and femoral head in an animal model.
abstract: OBJECTIVE
  The aim of this study was to compare the effects in terms of resistance to fracture of the mandibular condyle and femoral head following different doses of zoledronic acid in an animal model.
  
  
  METHODS
  A total of 80 adult male Sprague-Dawley rats were included in a prospective randomized study. The animals were randomly divided into four groups of 20 rats each. Group 1 (control) received sterile saline solution, while groups 2, 3 and 4 received a accumulated dose of 0.2 mg, 0.4 mg and 0.6 mg of zoledronic acid, respectively. The animals were sacrificed 28 days after the last dose, and the right hemimandible and the right femur were removed. The fracture strength was measured (in Newtons) with a universal test machine using a 1 kN load connected to a metal rod with one end angled at 30 degrees. The cross-head speed was 1 mm/min. Later, the specimens were observed under a scanning electron microscope with backscattered electron imaging (SEM-BSE). At last, chemical analysis and elemental mapping of the mineral bone composition were generated using a microanalytical system based on energy-dispersive and X-ray spectrometry (EDX).
  
  
  RESULTS
  A total of 160 fracture tests were performed. The fracture resistance increased in mandible and femur with a higher accumulated dose of zoledronic acid. Statistically significant differences were recorded versus the controls with all the studies groups. The chemical analysis in mandible showed a significantly increased of calcium and phosphorous to compare the control with all of the study groups; however, in femur no statistically significant differences between the four study groups were observed.
  
  
  CONCLUSIONS
  The administration of bisphosphonates increases the fracture resistance in mandible and femur.
authors.affiliation: Oral Medicine, University of Murcia, Murcia, Spain. fcamacho@um.es
authors.forename: Fabio
authors.initials: F
authors.lastname: Camacho-Alonso
authors.forename: Pía
authors.initials: P
authors.lastname: López-Jornet
authors.forename: Ascensión
authors.initials: A
authors.lastname: Vicente-Hernández
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005270:Femur Head / Q000293:injuries*; D006620:Hip Fractures / Q000517:prevention & control*; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008335:Mandibular Condyle / Q000293:injuries*; D008337:Mandibular Fractures / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid